Search results
Results from the WOW.Com Content Network
The agency also sent a warning letter to Veronvy, which offers unapproved and misbranded oral GLP-1 products, including one that claims to be approved by the FDA. US FDA warns online vendors ...
NEW YORK (Reuters) -U.S. Food and Drug Administration Commissioner Dr. Robert Califf said on Wednesday that he is very concerned about the prevalence of compounded and fake versions of highly in ...
The U.S. Food and Drug Administration (FDA) on Tuesday published letters warning two online vendors to stop selling unapproved versions of semaglutide and tirzepatide, the active ingredients in ...
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
Nycomed, a Swiss drug company which manufactures Actovegin, [18] claims it can be used for circulation and nutrition disturbances, skin grafting, burns, and wound-healing impairment. [19] Actovegin has also been used as a performance enhancer. [20] It has been investigated for use in treatment of polyneuropathy in diabetes, [21] and for stroke.
A review by the Memorial Sloan Kettering Cancer Center found no evidence that the Hoxsey Therapy was effective as a treatment for cancer. [48] Issels treatment – a regime recommended to be used alongside conventional treatment. It requires removal of metal fillings from the patient's mouth, and adherence to a restrictive diet.
The FDA said it found evidence the companies' websites offer the products, labeled for "research use only", for sale in the United States accompanied by claims such as weight loss, reducing the ...
Women who are pregnant or breastfeeding should not take enasidenib because it may cause harm to a developing fetus or a newborn baby. [4] Enasidenib was approved for medical use in the United States in August 2017. [2] [4] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [5]